Gamida Cell Ltd. (GMDA) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update
May 21, 2020 8:01 AM EDTPrimary endpoint achieved in global, randomized, Phase 3 study of omidubicel; Initiation of BLA submission planned for fourth quarter of 2020
Additional data from GDA-201 program expected in second half of 2020
$60 million follow-on offering expected to close today
Company to host conference call at 8:30 a.m. ET today
BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended March 31, 2020. The company... More
